Global Salivary Gland Cancer Market

Salivary Gland Cancer Comprehensive Study by Type (Parotid glands, Submandibular glands, Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes, Others), Treatment (Surgery, Radiotherapy, Chemotherapy), Diagnosis (Physical exam, Imaging tests, Others) Players and Region - Global Market Outlook to 2030

Salivary Gland Cancer Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Salivary Gland Cancer
Salivary gland cancer is an erratic disease in which cancer cells form in the tissues of the salivary glands. Most salivary gland tumors are benign and arise in the parotid glands. A painless salivary mass is the most general sign and is evaluated by fine-needle aspiration biopsy. Increasing incidence of salivary gland cancer is major driver for the market while other factors like increasing awareness about this disorder, the introduction of the new treatment or therapies and increasing demand from emerging markets drives the growth of the global market

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The salivary gland cancer market is expected to experience continued growth in the coming years, driven by factors like rising awareness, technological advancements, and the development of more effective and targeted therapies. However, addressing challenges like high treatment costs, limited access to care, and the need for continued research on rare subtypes remain crucial for improving the future of salivary gland cancer patients. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Salivary Gland Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer AG (Germany), Johnson & Johnson (United States), Loxo Oncology, Inc. (United States), Merck & Co., Inc. (United States), Plexxikon Inc. (United States), Taiwan Liposome Company, Ltd. (Taiwan), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Co (United States) and AstraZeneca Plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer Inc (United States), Daiichi Sankyo Co (Japan), Astellas Pharma Inc (Japan) and Novartis AG (Switzerland).

Segmentation Overview
AMA Research has segmented the market of Global Salivary Gland Cancer market by Type (Parotid glands, Submandibular glands and Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes and Others) and Region. On the basis of Type, Parotid glands are dominating the market in the year 2023 where as Submandibular glands stood as second largest market share.

On the basis of application, Hospitals & clinics segment is dominating the market in the year 2023 where as Medical research centers segment stood as second largest market .

On the basis of geography, the market of Salivary Gland Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Asia Pacific, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Salivary Gland Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Physical exam will boost the Salivary Gland Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The introduction of the new treatment or therapies and Increasing use of insurance facilities

Market Growth Drivers:
Increasing cases of salivary gland cancer and Growing awareness among the patients and rapidly improving healthcare infrastructure

Challenges:
Limited availability of required healthcare facilities

Restraints:
Lack of awareness about disorder

Opportunities:
Rising demand from emerging markets

Market Leaders and their expansionary development strategies
In December 2023, OncoSec joins forces with a clinical trial network to expand access to clinical trials investigating immunotherapy approaches for salivary gland cancer, accelerating research and development in this area.
In November 2023m OncoSec develops the ImmunoSCAPE Pan-Cancer Test, analyzing tumor immune microenvironment and identifying potential targets for immunotherapy approaches, offering hope for personalized treatment strategies in salivary gland cancer.
The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With numerous amendments, it is the most extensive law of its kind in the world. The law is intended to assure the consumer that foods are pure and wholesome, safe to eat, and produced under sanitary conditions; that drugs and devices are safe and effective for their intended uses; that cosmetics are safe and made from appropriate ingredients; and that all labeling and packaging is truthful, informative, and not deceptive

Key Target Audience
Salivary Gland Cancer Diagnostic and Treatment Supplies Companies, Salivary Gland Cancer Diagnostic and Treatment Supplies Providers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers and Potential Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Parotid glands
  • Submandibular glands
  • Sublingual glands
By Application
  • Hospitals & clinics
  • Medical research centers
  • Academic institutes
  • Others
By Treatment
  • Surgery
  • Radiotherapy
  • Chemotherapy

By Diagnosis
  • Physical exam
  • Imaging tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing cases of salivary gland cancer
      • 3.2.2. Growing awareness among the patients and rapidly improving healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Limited availability of required healthcare facilities
    • 3.4. Market Trends
      • 3.4.1. The introduction of the new treatment or therapies
      • 3.4.2. Increasing use of insurance facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Salivary Gland Cancer, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Salivary Gland Cancer (Value)
      • 5.2.1. Global Salivary Gland Cancer by: Type (Value)
        • 5.2.1.1. Parotid glands
        • 5.2.1.2. Submandibular glands
        • 5.2.1.3. Sublingual glands
      • 5.2.2. Global Salivary Gland Cancer by: Application (Value)
        • 5.2.2.1. Hospitals & clinics
        • 5.2.2.2. Medical research centers
        • 5.2.2.3. Academic institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Salivary Gland Cancer by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiotherapy
        • 5.2.3.3. Chemotherapy
      • 5.2.4. Global Salivary Gland Cancer by: Diagnosis (Value)
        • 5.2.4.1. Physical exam
        • 5.2.4.2. Imaging tests
        • 5.2.4.3. Others
      • 5.2.5. Global Salivary Gland Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Salivary Gland Cancer (Price)
      • 5.3.1. Global Salivary Gland Cancer by: Type (Price)
  • 6. Salivary Gland Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Loxo Oncology, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Plexxikon Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Taiwan Liposome Company, Ltd. (Taiwan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Co (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Salivary Gland Cancer Sale, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Salivary Gland Cancer (Value)
      • 7.2.1. Global Salivary Gland Cancer by: Type (Value)
        • 7.2.1.1. Parotid glands
        • 7.2.1.2. Submandibular glands
        • 7.2.1.3. Sublingual glands
      • 7.2.2. Global Salivary Gland Cancer by: Application (Value)
        • 7.2.2.1. Hospitals & clinics
        • 7.2.2.2. Medical research centers
        • 7.2.2.3. Academic institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Salivary Gland Cancer by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiotherapy
        • 7.2.3.3. Chemotherapy
      • 7.2.4. Global Salivary Gland Cancer by: Diagnosis (Value)
        • 7.2.4.1. Physical exam
        • 7.2.4.2. Imaging tests
        • 7.2.4.3. Others
      • 7.2.5. Global Salivary Gland Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Salivary Gland Cancer (Price)
      • 7.3.1. Global Salivary Gland Cancer by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Salivary Gland Cancer: by Type(USD Million)
  • Table 2. Salivary Gland Cancer Parotid glands , by Region USD Million (2018-2023)
  • Table 3. Salivary Gland Cancer Submandibular glands , by Region USD Million (2018-2023)
  • Table 4. Salivary Gland Cancer Sublingual glands , by Region USD Million (2018-2023)
  • Table 5. Salivary Gland Cancer: by Application(USD Million)
  • Table 6. Salivary Gland Cancer Hospitals & clinics , by Region USD Million (2018-2023)
  • Table 7. Salivary Gland Cancer Medical research centers , by Region USD Million (2018-2023)
  • Table 8. Salivary Gland Cancer Academic institutes , by Region USD Million (2018-2023)
  • Table 9. Salivary Gland Cancer Others , by Region USD Million (2018-2023)
  • Table 10. Salivary Gland Cancer: by Treatment(USD Million)
  • Table 11. Salivary Gland Cancer Surgery , by Region USD Million (2018-2023)
  • Table 12. Salivary Gland Cancer Radiotherapy , by Region USD Million (2018-2023)
  • Table 13. Salivary Gland Cancer Chemotherapy , by Region USD Million (2018-2023)
  • Table 14. Salivary Gland Cancer: by Diagnosis(USD Million)
  • Table 15. Salivary Gland Cancer Physical exam , by Region USD Million (2018-2023)
  • Table 16. Salivary Gland Cancer Imaging tests , by Region USD Million (2018-2023)
  • Table 17. Salivary Gland Cancer Others , by Region USD Million (2018-2023)
  • Table 18. South America Salivary Gland Cancer, by Country USD Million (2018-2023)
  • Table 19. South America Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 20. South America Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 21. South America Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 22. South America Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 23. Brazil Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 24. Brazil Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 25. Brazil Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 27. Argentina Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 28. Argentina Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 29. Argentina Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 30. Argentina Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 31. Rest of South America Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 34. Rest of South America Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 35. Asia Pacific Salivary Gland Cancer, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 39. Asia Pacific Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 40. China Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 41. China Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 42. China Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 43. China Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 44. Japan Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 45. Japan Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 46. Japan Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 47. Japan Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 48. India Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 49. India Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 50. India Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 51. India Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 52. South Korea Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 53. South Korea Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 54. South Korea Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 55. South Korea Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 56. Taiwan Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 57. Taiwan Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 58. Taiwan Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 59. Taiwan Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 60. Australia Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 61. Australia Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 62. Australia Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 63. Australia Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 68. Europe Salivary Gland Cancer, by Country USD Million (2018-2023)
  • Table 69. Europe Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 70. Europe Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 71. Europe Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 72. Europe Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 73. Germany Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 74. Germany Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 75. Germany Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 76. Germany Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 77. France Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 78. France Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 79. France Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 80. France Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 81. Italy Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 82. Italy Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 83. Italy Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 84. Italy Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 85. United Kingdom Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 88. United Kingdom Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 89. Netherlands Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 90. Netherlands Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 91. Netherlands Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 92. Netherlands Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 93. Rest of Europe Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 96. Rest of Europe Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 97. MEA Salivary Gland Cancer, by Country USD Million (2018-2023)
  • Table 98. MEA Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 99. MEA Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 100. MEA Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 101. MEA Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 102. Middle East Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 103. Middle East Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 104. Middle East Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 105. Middle East Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 106. Africa Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 107. Africa Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 108. Africa Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 109. Africa Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 110. North America Salivary Gland Cancer, by Country USD Million (2018-2023)
  • Table 111. North America Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 112. North America Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 113. North America Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 114. North America Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 115. United States Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 116. United States Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 117. United States Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 118. United States Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 119. Canada Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 120. Canada Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 121. Canada Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 122. Canada Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 123. Mexico Salivary Gland Cancer, by Type USD Million (2018-2023)
  • Table 124. Mexico Salivary Gland Cancer, by Application USD Million (2018-2023)
  • Table 125. Mexico Salivary Gland Cancer, by Treatment USD Million (2018-2023)
  • Table 126. Mexico Salivary Gland Cancer, by Diagnosis USD Million (2018-2023)
  • Table 127. Salivary Gland Cancer: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Salivary Gland Cancer: by Type(USD Million)
  • Table 138. Salivary Gland Cancer Parotid glands , by Region USD Million (2025-2030)
  • Table 139. Salivary Gland Cancer Submandibular glands , by Region USD Million (2025-2030)
  • Table 140. Salivary Gland Cancer Sublingual glands , by Region USD Million (2025-2030)
  • Table 141. Salivary Gland Cancer: by Application(USD Million)
  • Table 142. Salivary Gland Cancer Hospitals & clinics , by Region USD Million (2025-2030)
  • Table 143. Salivary Gland Cancer Medical research centers , by Region USD Million (2025-2030)
  • Table 144. Salivary Gland Cancer Academic institutes , by Region USD Million (2025-2030)
  • Table 145. Salivary Gland Cancer Others , by Region USD Million (2025-2030)
  • Table 146. Salivary Gland Cancer: by Treatment(USD Million)
  • Table 147. Salivary Gland Cancer Surgery , by Region USD Million (2025-2030)
  • Table 148. Salivary Gland Cancer Radiotherapy , by Region USD Million (2025-2030)
  • Table 149. Salivary Gland Cancer Chemotherapy , by Region USD Million (2025-2030)
  • Table 150. Salivary Gland Cancer: by Diagnosis(USD Million)
  • Table 151. Salivary Gland Cancer Physical exam , by Region USD Million (2025-2030)
  • Table 152. Salivary Gland Cancer Imaging tests , by Region USD Million (2025-2030)
  • Table 153. Salivary Gland Cancer Others , by Region USD Million (2025-2030)
  • Table 154. South America Salivary Gland Cancer, by Country USD Million (2025-2030)
  • Table 155. South America Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 156. South America Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 157. South America Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 158. South America Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 159. Brazil Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 160. Brazil Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 161. Brazil Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 162. Brazil Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 163. Argentina Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 164. Argentina Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 165. Argentina Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 166. Argentina Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 167. Rest of South America Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 168. Rest of South America Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 169. Rest of South America Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 170. Rest of South America Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 171. Asia Pacific Salivary Gland Cancer, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 173. Asia Pacific Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 174. Asia Pacific Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 175. Asia Pacific Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 176. China Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 177. China Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 178. China Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 179. China Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 180. Japan Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 181. Japan Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 182. Japan Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 183. Japan Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 184. India Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 185. India Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 186. India Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 187. India Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 188. South Korea Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 189. South Korea Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 190. South Korea Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 191. South Korea Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 192. Taiwan Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 193. Taiwan Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 194. Taiwan Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 195. Taiwan Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 196. Australia Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 197. Australia Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 198. Australia Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 199. Australia Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 204. Europe Salivary Gland Cancer, by Country USD Million (2025-2030)
  • Table 205. Europe Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 206. Europe Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 207. Europe Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 208. Europe Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 209. Germany Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 210. Germany Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 211. Germany Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 212. Germany Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 213. France Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 214. France Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 215. France Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 216. France Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 217. Italy Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 218. Italy Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 219. Italy Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 220. Italy Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 221. United Kingdom Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 222. United Kingdom Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 223. United Kingdom Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 224. United Kingdom Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 225. Netherlands Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 226. Netherlands Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 227. Netherlands Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 228. Netherlands Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 229. Rest of Europe Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 230. Rest of Europe Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 231. Rest of Europe Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 232. Rest of Europe Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 233. MEA Salivary Gland Cancer, by Country USD Million (2025-2030)
  • Table 234. MEA Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 235. MEA Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 236. MEA Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 237. MEA Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 238. Middle East Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 239. Middle East Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 240. Middle East Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 241. Middle East Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 242. Africa Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 243. Africa Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 244. Africa Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 245. Africa Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 246. North America Salivary Gland Cancer, by Country USD Million (2025-2030)
  • Table 247. North America Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 248. North America Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 249. North America Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 250. North America Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 251. United States Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 252. United States Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 253. United States Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 254. United States Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 255. Canada Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 256. Canada Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 257. Canada Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 258. Canada Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 259. Mexico Salivary Gland Cancer, by Type USD Million (2025-2030)
  • Table 260. Mexico Salivary Gland Cancer, by Application USD Million (2025-2030)
  • Table 261. Mexico Salivary Gland Cancer, by Treatment USD Million (2025-2030)
  • Table 262. Mexico Salivary Gland Cancer, by Diagnosis USD Million (2025-2030)
  • Table 263. Salivary Gland Cancer: by Type(USD/Units)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Salivary Gland Cancer: by Type USD Million (2018-2023)
  • Figure 5. Global Salivary Gland Cancer: by Application USD Million (2018-2023)
  • Figure 6. Global Salivary Gland Cancer: by Treatment USD Million (2018-2023)
  • Figure 7. Global Salivary Gland Cancer: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Salivary Gland Cancer Share (%), by Country
  • Figure 9. Asia Pacific Salivary Gland Cancer Share (%), by Country
  • Figure 10. Europe Salivary Gland Cancer Share (%), by Country
  • Figure 11. MEA Salivary Gland Cancer Share (%), by Country
  • Figure 12. North America Salivary Gland Cancer Share (%), by Country
  • Figure 13. Global Salivary Gland Cancer: by Type USD/Units (2018-2023)
  • Figure 14. Global Salivary Gland Cancer share by Players 2023 (%)
  • Figure 15. Global Salivary Gland Cancer share by Players (Top 3) 2023(%)
  • Figure 16. Global Salivary Gland Cancer share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 22. Loxo Oncology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Loxo Oncology, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Plexxikon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Plexxikon Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Taiwan Liposome Company, Ltd. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 29. Taiwan Liposome Company, Ltd. (Taiwan) Revenue: by Geography 2023
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 32. Bristol-Myers Squibb Co (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb Co (United States) Revenue: by Geography 2023
  • Figure 34. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 36. Global Salivary Gland Cancer: by Type USD Million (2025-2030)
  • Figure 37. Global Salivary Gland Cancer: by Application USD Million (2025-2030)
  • Figure 38. Global Salivary Gland Cancer: by Treatment USD Million (2025-2030)
  • Figure 39. Global Salivary Gland Cancer: by Diagnosis USD Million (2025-2030)
  • Figure 40. South America Salivary Gland Cancer Share (%), by Country
  • Figure 41. Asia Pacific Salivary Gland Cancer Share (%), by Country
  • Figure 42. Europe Salivary Gland Cancer Share (%), by Country
  • Figure 43. MEA Salivary Gland Cancer Share (%), by Country
  • Figure 44. North America Salivary Gland Cancer Share (%), by Country
  • Figure 45. Global Salivary Gland Cancer: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Johnson & Johnson (United States)
  • Loxo Oncology, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Plexxikon Inc. (United States)
  • Taiwan Liposome Company, Ltd. (Taiwan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bristol-Myers Squibb Co (United States)
  • AstraZeneca Plc (United Kingdom)
Additional players considered in the study are as follows:
Pfizer Inc (United States) , Daiichi Sankyo Co (Japan) , Astellas Pharma Inc (Japan) , Novartis AG (Switzerland)
Select User Access Type

Key Highlights of Report


Jan 2024 150 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Salivary Gland Cancer Market Quantitative research analysis
Global Salivary Gland Cancer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer AG (Germany), Johnson & Johnson (United States), Loxo Oncology, Inc. (United States), Merck & Co., Inc. (United States), Plexxikon Inc. (United States), Taiwan Liposome Company, Ltd. (Taiwan), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Co (United States) and AstraZeneca Plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The introduction of the new treatment or therapies " is seen as one of major influencing trends for Salivary Gland Cancer Market during projected period 2023-2030.
The Salivary Gland Cancer market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Salivary Gland Cancer Market Report?

Have a Query? Click Here

Other Related Reports

Leprosy Treatment Comprehensive Study by Type (Borderline Tuberculoid, Tuberculoid, Borderline, Histoid, Others), Drug Type (Antibacterial, Leprostatics, Antitubercular, Others), Leprosy Type (Multib...
$ 3450
Malabsorption Syndrome Comprehensive Study by Application (Pharmaceutical Companies, Hospitals, Nutrition Clinics, Academic And Research Institutes), Treatment (Nutritional Supplements, Gluten-Free D...
$ 3750
Argininemia Treatment Comprehensive Study by Type (Oral, Injection), End Users (Hospitals, Clinics, Therapeutic Centres), Category (Congenital and Genetic Diseases, Metabolic disorders, RDCRN), Treat...
$ 3450
Dynamic SPECT Comprehensive Study by Application (Myocardial perfusion imaging, Functional brain imaging, Applications in nuclear technology, Others), Imaging Technique (Hybrid SPECT, Standalone SPEC...
$ 3750
Picato Gel Comprehensive Study by Type (Type I, Type II), Application (Actinic Keratosis, Keratosis), Distribution Channel (Direct Sale, Distributor) Players and Region - Global Market Outlook to 203...
$ 3500
Soft Tissue Repair Comprehensive Study by Type (Fixation Products (Suture, Suture Anchors, Interference Screw), Tissue Patch/Match (Biological {Allograft, Xenograft},Synthetic), Laparoscopic Instrume...
$ 3750